ex10_1.htm


    
      

    

    Exhibit
      10.1

     

    SECURITIES
      PURCHASE AGREEMENT

    


    This
      SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into
      as of December 17, 2007, by and between Rexahn Pharmaceuticals, Inc., a Delaware
      corporation (the “Company”), and Jungwoo Family Co., Ltd., a Korean
      corporation (the “Purchaser”).

    


    Recitals

    


    The
      Company and the Purchaser are executing and delivering this Agreement in
      reliance upon the exemption from securities registration afforded by
      Section 4(2) under the Securities Act of 1933, as amended (the “1933
      Act”), and the provisions of Regulation D (“Regulation D”)
      and/or Regulation S (“Regulation S”), each as promulgated by the
      U.S. Securities and Exchange Commission (the “SEC”) under the 1933
      Act.

    


    The
      Purchaser wishes to purchase, and the Company wishes to sell and issue to the
      Purchaser, upon the terms and subject to the conditions stated in this
      Agreement, (i) 1,428,571 shares (the “Initial Shares”) of its common
      stock, par value US$0.0001 per share (the “Common Stock”), and
      (ii) warrants, in substantially the form attached hereto as
Exhibit A (each a “Warrant”), to acquire up to 285,714 shares
      of Common Stock (the “Warrant Shares”) at an exercise price of US$1.80
      per share, for aggregate cash consideration of US$1,999,999.40 (the “Purchase
      Price”).

    


    Agreement

    


    NOW,
      THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
      and for other good and valuable consideration, the receipt and sufficiency
      of
      which is hereby acknowledged, the Company and the Purchaser agree as
      follows:

    


    1.           DEFINITIONS.  In
      addition to those terms defined above and elsewhere in this Agreement, for
      the
      purposes of this Agreement, the following terms shall have the meanings here
      set
      forth:

    


    1.1           “1934
      Act” means the Securities Exchange Act of 1934, as amended.

    


    1.2           “Affiliate”
      means, with respect to any Person, any other Person that directly or indirectly
      through one or more intermediaries controls, is controlled by or is under common
      control with, such Person, as such terms are used in and construed under
      Rule 144 under the 1933 Act.

    


    1.3           “Business
      Day” means any day other than Saturday, Sunday or any other day on which
      commercial banks in the City of New York are authorized or required by law
      to
      remain closed.


    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    


    1.4           “Closings”
      means the Initial Closing and the Final Closing, collectively.

    


    1.5           “Effective
      Date” means the date that the Registration Statement is first declared
      effective by the SEC.

    


    1.6           “Eligible
      Market” means any of the New York Stock Exchange, the American Stock
      Exchange, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ
      Capital Market or the NASD Over-the-Counter Bulletin Board.

    


    1.7           “Final
      Closing” means the final closing of the purchase and sale of the Securities
      pursuant to Section 2.4.

    


    1.8           “Final
      Closing Date” means the date and time of the Final Closing.

    


    1.9           “Initial
      Closing” means the initial closing of the purchase and sale of the
      Securities pursuant to Section 2.3.

    


    1.10           “Initial
      Closing Date” means the date and time of the Initial Closing.

    


    1.11           “Lien”
      means any lien, charge, claim, security interest, encumbrance, right of first
      refusal or other restriction.

    


    1.12           “Material
      Adverse Effect” means a material adverse effect on (i) the condition
      (financial or otherwise), business, assets or results of operations of the
      Company,  (ii) the Company’s ability to perform any of its
      obligations under the terms of the Transaction Documents in any material respect
      or (iii) the rights and remedies of the Purchaser under the Transaction
      Documents.

    


    1.13           “Person”
      means an individual, corporation, partnership, limited liability company, trust,
      business trust, association, joint stock company, joint venture, pool,
      syndicate, sole proprietorship, unincorporated organization, governmental
      authority or any other form of entity not specifically listed
      herein.

    


    1.14           “Registration
      Rights Agreement” means a Registration Rights Agreement substantially in the
      form of Exhibit B hereto.

    


    1.15           “Registration
      Statement” means a registration statement meeting the requirements set forth
      in the Registration Rights Agreement and covering the resale of the Initial
      Shares and the Warrant Shares.

    


    1.16           “Securities”
      means the Common Stock, the Warrants and the Warrant Shares issued or issuable
      pursuant to the Transaction Documents.

    


    1.17           “Subsidiary”
      means any Person in which the Company, directly or indirectly, owns capital
      stock or holds an equity or similar interest.


    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    


    1.18           “Trading
      Day” means (a) any day on which the Common Stock is listed or quoted
      and traded on its primary Trading Market, (b) if the Common Stock is not
      then listed or quoted and traded on any Eligible Market, then a day on which
      trading occurs on the NASDAQ Global Market (or any successor thereto), or
      (c) if trading ceases to occur on the NASDAQ Global Market (or any
      successor thereto), any Business Day.

    


    1.19           “Trading
      Market” means the NASD Over-the-Counter Bulletin Board or any other Eligible
      Market, or any other national securities exchange, market or trading or
      quotation facility on which the Common Stock is then listed or
      quoted.

    


    1.20           “Transaction
      Documents” means this Agreement, the Registration Rights Agreement, the
      Warrants and any other agreement entered into, now or in the future, by the
      Company in connection with this Agreement or any of the other Transaction
      Documents.

    


    1.21           List
      of Additional Definitions.  The following is a list of additional
      terms used in this Agreement and a reference to the Section hereof in which
      such
      term is defined:

    


    
      	
              Term

            	
              Section

            
	
              Action

            	
              3.8

            
	
              Additional
                Shares of Stock

            	
              5.7(b)

            
	
              Adjusted
                Initial Shares

            	
              5.7(b)

            
	
              Adjusted
                Purchase Price

            	
              5.7(b)

            
	
              Aggregate
                Consideration

            	
              5.7(b)

            
	
              Agreement

            	
              Preamble

            
	
              Common
                Stock

            	
              Recitals

            
	
              Company

            	
              Preamble

            
	
              Diluted
                Price

            	
              5.7(a)

            
	
              Initial
                Shares

            	
              Recitals

            
	
              Make-Whole
                Number

            	
              5.7(b)

            
	
              Purchase
                Price

            	
              Recitals

            
	
              Purchaser

            	
              Preamble

            
	
              Regulation
                D

            	
              Recitals

            
	
              Regulation
                S

            	
              Recitals

            
	
              SEC

            	
              Recitals

            
	
              U.S.
                Person

            	
              4.2

            
	
              Warrants

            	
              Recitals

            
	
              Warrant
                Shares

            	
              Recitals

            
	
              1933
                Act

            	
              Preamble

            


    

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    


    2.          PURCHASE
      AND SALE OF SECURITIES.

    


    2.1           Purchase
      of the Initial Shares and Warrants.  Subject to the terms and
      conditions of this Agreement and on the basis of the representations and
      warranties made herein, the Company hereby agrees to sell and issue to the
      Purchaser, and the Purchaser hereby agrees to purchase from the Company, the
      Initial Shares and the Warrant for cash in an amount equal to the Purchase
      Price.

    


    2.2           Time
      and Place of Closings.  The Closings shall take place at the
      offices of Chadbourne & Parke LLP, 1200 New Hampshire Avenue, N.W.,
      Washington, DC  20036.  The Initial Closing shall take place
      on December 24, 2007, and the Final Closing shall take place on February 29,
      2008.

    


    2.3           Initial
      Closing Deliveries.

    


    (a)           At
      the Initial Closing, the Company shall deliver or cause to be delivered to
      the
      Purchaser the following:

    


    (i)           a
      stock certificate, free and clear of all restrictive legends (except as
      expressly provided in Section 5.1(b)), evidencing 142,857 shares of
      Common Stock, registered in the name of the Purchaser;

    


    (ii)           a
      Warrant, issued in the name of the Purchaser, exercisable for up to 28,571
      Warrant Shares;

    


    (iii)           a
      copy of the Registration Rights Agreement executed on behalf of the Company;
      and

    


    (iv)           any
      other documents reasonably requested by the Purchaser or its counsel in
      connection with the Initial Closing, including, without limitation, certified
      copies of the Company’s certificate of incorporation, certificates of good
      standing and customary officers’ and secretary’s certificates.


    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    


    (c)           At
      the Initial Closing, the Purchaser shall deliver or cause to be delivered to
      the
      Company cash in an amount equal to US$199,999.80 by wire transfer of immediately
      available federal funds to the account of the Company.

    


    2.4           Final
      Closing Deliveries.

    


    (a)           At
      the Final Closing, the Company shall deliver or cause to be delivered to the
      Purchaser the following:

    


    (i)           a
      stock certificate, free and clear of all restrictive legends (except as
      expressly provided in Section 6.1(b)), evidencing 1,285,714 shares
      of Common Stock, registered in the name of the Purchaser;

    


    (ii)           a
      Warrant, issued in the name of the Purchaser, exercisable for up to 257,143
      Warrant Shares;

    


    (iii)           any
      other documents reasonably requested by the Purchaser or its counsel in
      connection with the Closing, including, without limitation, certified copies
      of
      the Company’s certificate of incorporation, certificates of good standing and
      customary officers’ and secretary’s certificates.

    


    (c)           At
      the Final Closing, the Purchaser shall deliver or cause to be delivered to
      the
      Company cash in an amount equal to the Purchase Price of US$1,799,999.60 by
      wire
      transfer of immediately available federal funds to the account of the
      Company.

    


    2.5           Use
      of Proceeds.  The Company will use the net proceeds of the
      issuance and sale of Initial Shares and the Warrants for its general working
      capital and other corporate purposes.

    


    3.           REPRESENTATIONS
      AND WARRANTIES OF THE COMPANY.  The Company hereby represents and
      warrants to the Purchaser as follows:

     

    3.1           Subsidiaries.  The
      Company has no direct or indirect Subsidiaries other than those listed in
Schedule 3.1.  Except as disclosed in
Schedule 3.1, the Company owns, directly or indirectly, all of the
      capital stock or comparable equity interests of each Subsidiary free and clear
      of any Lien, and all the issued and outstanding shares of capital stock or
      comparable equity interests of each Subsidiary are validly issued and are fully
      paid, non-assessable and free of preemptive and similar rights.

    


    3.2           Organization
      and Good Standing.  Each of the Company and each Subsidiary is a
      corporation validly existing and in good standing under the laws of the
      jurisdiction of its incorporation or organization (as applicable), with all
      requisite power and authority to carry on its business as presently conducted
      and own and use its properties and assets.  Each of the Company and
      each Subsidiary is authorized to conduct business as a foreign corporation
      and
      is in good standing in each jurisdiction where the conduct of its business
      or
      the ownership of its property requires such qualification, except where the
      failure to be so qualified and in good standing would not, individually or
      in
      the aggregate, reasonably be expected to have or result in a Material Adverse
      Effect.


    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    


    3.3           Authorization;
      Enforcement.  The Company has the requisite corporate power and
      authority to enter into and to consummate the transactions contemplated by
      each
      of the Transaction Documents and otherwise to carry out its obligations
      hereunder and thereunder.  The execution and delivery of each of the
      Transaction Documents by the Company and the consummation by it of the
      transactions contemplated hereunder and thereunder have been duly authorized
      by
      all necessary action on the part of the Company and no further action is
      required by the Company in connection therewith.  Each Transaction
      Document has been (or upon delivery will have been) duly executed by the Company
      and, when delivered in accordance with the terms hereof, will constitute the
      valid and binding obligation of the Company enforceable against the Company
      in
      accordance with its terms.

    


    3.4           No
      Conflicts.  The execution, delivery and performance of the
      Transaction Documents by the Company and the consummation by the Company of
      the
      transactions contemplated hereby and thereby do not and will not
      (a) conflict with or violate any provision of the Company’s or any
      Subsidiary’s certificate or articles of incorporation, bylaws or other
      organizational or charter documents, (b) conflict with, or constitute a
      default (or an event that with notice or lapse of time or both would become
      a
      default) under, or give to others any rights of termination, amendment,
      acceleration or cancellation (with or without notice, lapse of time or both)
      of,
      any agreement, credit facility, debt or other instrument (evidencing a Company
      or Subsidiary debt or otherwise) or other understanding to which the Company
      or
      any Subsidiary is a party or by which any property or asset of the Company
      or
      any Subsidiary is bound or affected, or (c) result in a violation of any
      law, rule, regulation, order, judgment, injunction, decree or other restriction
      of any court or governmental authority to which the Company or a Subsidiary
      is
      subject (assuming the accuracy of the Purchaser’s representations and warranties
      and compliance by the Purchaser with its respective covenants as set forth
      in
      this Agreement), including federal and state securities laws and regulations
      and
      the rules and regulations of any self-regulatory organization to which the
      Company or its securities are subject, or by which any property or asset of
      the
      Company or a Subsidiary is bound or affected; except in the case of each of
      clauses (b) and (c), such as would not, individually or in the aggregate,
      reasonably be expected to have or result in a Material Adverse
      Effect.

    


    3.5           Issuance
      of the Securities.  The Securities have been duly
      authorized.  The Initial Shares and Warrant, when issued and paid for
      in accordance with the terms of this Agreement, and the Warrant Shares issuable
      upon exercise of the Warrant when so issued and paid for in accordance with
      the
      terms of the Warrant, will be validly issued, fully paid and nonassessable,
      and
      free and clear of all Liens and charges and shall not be subject to preemptive
      or similar rights.  The Company has reserved from its duly authorized
      capital stock the maximum number of shares of Common Stock to be issued to
      the
      Purchaser upon exercise of the Securities.  Assuming the continued
      validity of the Purchaser’s representations and warranties contained in
Section 4, the offer, issuance and sale of the Securities to the
      Purchaser pursuant to this Agreement and upon exercise of the Warrant are exempt
      from registration requirements of the 1933 Act.

    


    3.6           Capitalization.  The
      aggregate number of shares and type of all authorized, issued and outstanding
      capital stock, options and other securities of the Company (whether or not
      presently convertible into or exercisable or exchangeable for shares of capital
      stock of the Company) as of the date hereof is set forth in
Schedule 3.6.  All outstanding shares of capital stock are
      duly authorized, validly issued, fully paid and nonassessable and have been
      issued in compliance with all applicable securities laws.  Except as
      set forth in Schedule 3.61
      and except for customary adjustments as a result of stock dividends, stock
      splits, combinations of shares, reorganizations, recapitalizations,
      reclassifications or other similar events, as of the date hereof there are
      no
      anti-dilution or price adjustment provisions contained in any security issued
      by
      the Company (or in any agreement providing rights to security
      holders).  The issuance and sale of the Securities will not obligate
      the Company to issue shares of Common Stock or other securities to any Person
      (other than the Purchasers) and will not result in a right of any holder of
      Company securities to adjust the exercise, conversion, exchange or reset price
      under such securities


    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    


    3.7           Answer
      to all Inquires.  The Company has answered all inquiries that the
      Purchaser has made of it concerning the Company, its business and financial
      condition, or any other matter relating to the operation of the Company and
      the
      offering and sale of the Initial Shares and Warrant. No written statement or
      inducement that is contrary to the information conveyed to the Purchaser that
      if
      untrue would have a material effect on the Company’s business taken as a whole
      has been made by or on behalf of the Company to the Purchaser.

    


    3.8           Absence
      of Litigation.  Except as set forth in Schedule 3.8,
      there is no action, suit, inquiry, notice of violation, proceeding or
      investigation pending or, to the knowledge of the Company, threatened against
      or
      affecting the Company, any Subsidiary, any of the Company’s officers or
      directors in their capacities as such and any of their respective properties
      before or by any court, arbitrator, governmental or administrative agency or
      regulatory authority (federal, state, county, local or foreign) (collectively,
      an “Action”) which (a) adversely affects or challenges the legality,
      validity or enforceability of any of the Transaction Documents or the Securities
      or (b) could, if there were an unfavorable decision, individually or in the
      aggregate, have or result in a Material Adverse Effect.  To the
      knowledge of the Company, no judgment, injunction, writ, award, decree or order
      has been issued by any court or other governmental authority against the
      Company.

    


    3.9           Labor
      Relations.  No material labor dispute exists or, to the knowledge
      of the Company is imminent, with respect to any of the employees of the
      Company.

    


    3.10           Compliance.  Neither
      the Company nor any Subsidiary (i) is in default under or in violation of (and
      no event has occurred that has not been waived that, with notice or lapse of
      time or both, would result in a default by the Company or any Subsidiary under),
      nor has the Company or any Subsidiary received notice of a claim that it is
      in
      default under or that it is in violation of, any indenture, loan or credit
      agreement or any other agreement or instrument to which it is a party or by
      which it or any of its properties is bound (whether or not such default or
      violation has been waived), (ii) is in violation of any order of any court,
      arbitrator or governmental body, or (iii) is or has been in violation of any
      statute, rule or regulation of any governmental authority, including without
      limitation all foreign, federal, state and local laws relating to taxes,
      environmental protection, occupational health and safety, product quality and
      safety and employment and labor matters, except in each case as could not,
      individually or in the aggregate, reasonably be expected to have or result
      in a
      Material Adverse Effect.

    

      

    

    
        
        1
          Ted: Revise
          schedules to reflect anti-dilution rights accorded to KT&G, Rexgene,
          etc.


        
          
            
            

          

          
            7

            
              

            

          

          
            
            

          

        



    

    3.11           Transactions
      with Affiliates and Employees.  Except as set forth in Schedule
      3.11, none of the officers or directors of the Company and, to the knowledge
      of the Company, none of the employees of the Company is presently a party to
      any
      transaction with the Company or any Subsidiary (other than for services as
      employees, officers and directors), including any contract, agreement or other
      arrangement providing for the furnishing of services to or by, providing for
      rental of real or personal property to or from, or otherwise requiring payments
      to or from any officer, director or such employee or, to the knowledge of the
      Company, any entity in which any officer, director, or any such employee has
      a
      substantial interest or is an officer, director, trustee or
      partner.

    


    3.12           Title
      to Assets.  The Company and its Subsidiaries have valid title to
      or leasehold rights for all real property that is material to the business
      of
      the Company and the Subsidiaries and good and marketable title in all personal
      property owned by them that is material to the business of the Company and
      the
      Subsidiaries, in each case free and clear of all Liens, except for Liens
      disclosed in Schedule 3.12 or as do not, individually or in the
      aggregate, materially interfere with the use made and proposed to be made of
      such property by the Company and the Subsidiaries.  Any real property
      and facilities held under lease by the Company and its Subsidiaries are held
      by
      them under valid, subsisting and enforceable leases of which the Company and
      the
      Subsidiaries are in compliance; except as would not, individually or in the
      aggregate, reasonably be expected to have or result in a Material Adverse
      Effect.

    


    3.13           Registration
      Rights.  Except as described in Schedule 3.13,3 as of the date hereof
      the Company has not
      granted or agreed to grant to any Person any rights (including “piggy-back”
registration rights) to have any securities of the Company registered with
      the
      SEC or any other governmental authority that have not been satisfied or
      waived.

    


    3.14           Form SB-2
      Eligibility.  The Company is eligible to register the resale of
      its Common Stock for resale by the Purchasers under Form SB-2 promulgated
      under the 1933 Act.

    


    3.15           Disclosure.  All
      disclosures provided to the Purchaser regarding the Company, its business and
      the transactions contemplated hereby, including the Schedules to this Agreement,
      furnished by or on behalf of the Company are true and correct in all material
      respects and do not contain any untrue statement of a material fact to the
      extent of the Company’s knowledge.  Except for the transactions
      contemplated by this Agreement, no event or circumstance has occurred or
      information exists with respect to the Company or any of its Subsidiaries or
      its
      or their business, properties, prospects, operations or financial conditions,
      which, under applicable law, rule or regulation, requires public disclosure
      or
      announcement by the Company but which has not been so publicly announced or
      disclosed.

    

      

    

      
      2 Ted:  Revise
        schedules to reflect that other parties (KT&G, etc.) now have registration
        rights.

      

        
          
            
            

          

          
            8

            
              

            

          

          
            
            

          

        

      

       

    

    4.           REPRESENTATIONS
      AND WARRANTIES OF THE PURCHASER.  The Purchaser hereby represents
      and warrants to the Company as follows as of the date hereof, the Initial
      Closing Date and the Final Closing Date:

    


    4.1           Organization;
      Authority.  The Purchaser is a corporation duly organized, validly
      existing and in good standing under the laws of the Republic of
      Korea.  The Purchaser has the requisite corporate power and authority
      to enter into and to consummate the transactions contemplated by the Transaction
      Documents to which it is a party and otherwise to carry out its obligations
      hereunder and thereunder.  The execution, delivery and performance by
      the Purchaser of the Transaction Documents to which it is a party have been
      duly
      authorized by all necessary action on the part of the Purchaser.  Each
      Transaction Document to which the Purchaser is a party has been (or upon
      delivery will have been) duly executed by the Purchaser and, when delivered
      by
      the Purchaser in accordance with terms hereof, will constitute the valid and
      legally binding obligations of the Purchaser, enforceable against it in
      accordance with its terms.

    


    4.2           The
      Purchaser’s Status.  At the time the Purchaser was offered the
      Securities, it was, and at the date hereof it is, an “accredited investor” as
      defined in Rule 501(a) under the 1933 Act.  The Purchaser is not
      a broker-dealer, or required to be registered as a broker-dealer, under
      Section 15 of the 1934 Act.  The Purchaser is not a U.S. person
      within the meaning of Rule 902(k) of Regulation S under the 1933 Act
      (“U.S. Person”), which term includes: (i) a natural person resident
      in the United States; (ii) a partnership or corporation organized or
      incorporated under the laws of the United States; (iii) an estate of which
      any executor or administrator is a U.S. Person; (iv) a trust of which any
      trustee is a U.S. Person (other than a trust of which any professional fiduciary
      duty acting as trustee is a U.S. Person, if a trustee who is not a U.S. Person
      has sole or shared investment discretion with respect to the trust assets,
      and
      no beneficiary of the trust (and no settler if the trust is revocable) is a
      U.S.
      Person); (v) an agency or branch of a foreign entity located in the United
      States; (vi) a non-discretionary account or similar account (other than an
      estate or trust) held by a dealer or other fiduciary for the benefit or account
      of a U.S. Person; (vii) a discretionary account or similar account (other
      than an estate or trust) held by a dealer or other fiduciary organized,
      incorporated or (if an individual) resident in the United States; and
      (viii) a partnership or corporation (A) organized or incorporated
      under the laws of any foreign jurisdiction and (B) formed by a U.S. Person
      principally for the purpose of investing in securities not registered under
      the
      1933 Act, unless it is organized or incorporated, and owned, by accredited
      investors (as defined in Rule 501(a) under the 1933 Act) who are not
      natural persons, estates or trusts.

    


    4.3           Experience
      of the Purchaser; Substantial Risk of Loss.  The Purchaser, either
      alone or together with its representatives, has such knowledge, sophistication
      and experience in business and financial matters so as to be capable of
      evaluating the merits and risks of the prospective investment in the Securities,
      and has so evaluated the merits and risks of such investment, and the Purchaser
      has had available such information with respect to the Company as the Purchaser
      deems necessary or appropriate to make such evaluation and an informed
      investment decision with respect thereto. The Purchaser is able to bear the
      economic risk of an investment in the Securities and, at the present time,
      is
      able to afford a complete loss of such investment.   The
      Purchaser has discussed with its professional legal, tax and financial advisors,
      to the extent it deemed appropriate, the suitability of the investment in the
      Securities for its particular tax and financial situation.


    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    


    4.4           Manner
      and Place of Solicitation.  The Purchaser is not purchasing the
      Securities as a result of any advertisement, article, notice or other
      communication regarding the Securities published in any newspaper, magazine
      or
      similar media or broadcast over television or radio or presented at any seminar
      or any other general solicitation or general advertisement. The Purchaser has not
      been
      offered the Securities in the United States and at the time of execution of
      this
      Agreement is physically outside the United States.

    


    4.5           No
      Public Sale or Distribution; Investment Intent.  The Purchaser is
      acquiring the Securities in the ordinary course of business for its own account
      for investment purposes only and not on behalf or for the benefit of any U.S.
      Person or with a view towards, or for resale in connection with, the public
      sale
      or distribution thereof, and the Purchaser does not have a present intention
      nor
      a present arrangement to effect any distribution of the Securities to or through
      any person or entity.  Except as expressly contemplated by the
      Transaction Documents, the sale and resale of the Securities has not been
      pre-arranged with any U.S. Person or buyer in the United States, and the
      Purchaser has no present plans to enter into any contract, undertaking,
      agreement or arrangement for the distribution, resale, subdivision or
      fractionalization of the Securities. In order to induce the Company to issue
      and
      sell the Securities subscribed for hereby, the Purchaser agrees that the Company
      will have no obligation to recognize the ownership, beneficial or otherwise,
      of
      the Securities by anyone but the Purchaser.  Notwithstanding the
      foregoing, by making the representations herein, the Purchaser does not agree
      to
      hold any of the Securities for any minimum or other specific term and reserves
      the right to dispose of the Securities at any time in accordance with or
      pursuant to an effective registration statement or an exemption under the 1933
      Act.

    


    4.6           Information
      Regarding the Company.  The Purchaser has been furnished with or
      has had access to all publicly available documents and records of the Company
      so
      as to allow the Purchaser to understand and evaluate such records and documents
      fully.  In addition, the Purchaser has received from the Company such
      other information concerning its operations, financial condition and other
      matters as the Purchaser has requested and considered all factors the Purchaser
      deems material in deciding on the advisability of investing in the
      Securities.  In evaluating the suitability of an investment in the
      Company, the Purchaser has not been furnished and has not relied upon any
      representations or other information (whether oral or written) other than as
      set
      forth herein or in the publicly available documents and records of the
      Company.  The Purchaser has not relied on any projections in making an
      investment decision with respect to the Securities.


    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    


    4.7           No
      Distribution.  The Purchaser has not distributed the records and
      documents the Company provided to the Purchaser under or in connection with
      this
      Agreement to any other Person.

    


    4.8           Information
      Regarding the Purchaser.  All information which the Purchaser has
      provided to the Company concerning itself, its financial position, and the
      knowledge of financial and business matters of the person making the investment
      decision on behalf of the  Purchaser, including all information
      contained herein, is true and complete as of the date of this Agreement and
      will
      be true and complete as of the Closing Date. If in any respect the
      representations and warranties of the Purchaser contained herein and all other
      information that the Purchaser has provided to the Company shall not be true
      and
      accurate at any time prior to the Final Closing Date, the Purchaser agrees
      to
      give prompt written notice of such fact to the Company, specifying which
      representations, warranties or information are not true and accurate and the
      reasons therefor.  The Purchaser understands that the offering and
      sale of the Securities is intended to be exempt from registration under the
      1933
      Act, by virtue of Regulation D and/or Regulation S of the 1933 Act, and
      from applicable U.S. or foreign federal or state securities laws based, in
      part,
      upon the representations, warranties and agreements contained in this Agreement
      and that the Company may rely on such representations, warranties and agreements
      in connection therewith.

    


    4.9           Regulation
      S Compliance.  The address set forth in Section 7.2 of this
      Agreement is the Purchaser’s true and correct residence or principal place of
      business and the Purchaser has no present intention of becoming a resident
      of
      any state or other jurisdiction of the United States or moving its principal
      place of business within the United States. The Purchaser acknowledges and
      agrees that until the expiration of the one-year distribution compliance period
      within the meaning of Rule 902(f) of Regulation S under the 1933 Act,
      the Purchaser will only resell the Securities in compliance with the provisions
      of Regulation S, pursuant to registration under the 1933 Act or pursuant to
      an exemption from registration.  The Purchaser agrees not to engage in
      hedging transactions with regard to the Securities unless in compliance with
      the
      1933 Act.

    


    5.           COVENANTS
      AND AGREEMENTS.

    


    5.1           Transfer
      Restrictions.

    


    (a)           The
      Purchaser covenants that the Securities will only be disposed of pursuant to
      an
      effective registration statement under the 1933 Act or pursuant to an available
      exemption from the registration requirements of the 1933 Act, and in compliance
      with any applicable state securities laws.  In connection with any
      transfer of Securities other than pursuant to an effective registration
      statement or to the Company or pursuant to Rule 144(k) under the 1933 Act,
      the Company may require the transferor to provide to the Company an opinion
      of
      counsel selected by the transferor and reasonably acceptable to the Company,
      the
      form and substance of which opinion shall be reasonably satisfactory to the
      Company, to the effect that such transfer does not require registration under
      the 1933 Act.  Notwithstanding the foregoing, the Company hereby
      consents to and agrees to register on the books of the Company without any
      such
      legal opinion, any transfer of Securities by the Purchaser to an Affiliate
      of
      the Purchaser, provided that the transferee certifies to the Company
      that it is an “accredited investor” as defined in Rule 501(a) promulgated
      under the 1933 Act.


    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    


    (b)           The
      Purchaser agrees to the imprinting, except as otherwise permitted by
Section 5.1(c), of a legend in substantially the following form on
      any certificate evidencing Securities:

    


    THE
      SECURITIES REPRESENTED BY THIS CERTIFICATE [AND THE SECURITIES ISSUABLE UPON
      EXERCISE HEREOF] HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
      AS
      AMENDED (THE “SECURITIES ACT”) OR ANY OTHER U.S. OR FOREIGN SECURITIES LAWS,
      AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, HYPOTHECATED OTHERWISE TRANSFERRED
      UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE U.S. AND FOREIGN
      SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
      NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
      COMPLIANCE WITH APPLICABLE U.S. AND FOREIGN SECURITIES LAWS.  THE
      COMPANY MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
      TO THE EFFECT THAT ANY PROPOSED OFFER, SALE, HYPOTHECATION OR OTHER TRANSFER
      IS
      IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES
      LAWS.  HEDGING TRANSACTIONS INVOLVING THE SECURITIES REPRESENTED BY
      THIS CERTIFICATE [AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF] MAY NOT
      BE
      CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

    


    (c)           Certificates
      evidencing Securities shall not be required to contain the legend set forth
      in
Section 5.1(b) or any other legend if such Securities are
      eligible for sale under Rule 144(k) under the 1933 Act or if such legend is
      not required under applicable requirements of the 1933 Act (including judicial
      interpretations and pronouncements issued by the Staff of the
      SEC).  Following such time as a legend is no longer required for
      certain Securities, the Company will, no later than ten Trading Days following
      the delivery by the Purchaser to the Company of a legended certificate
      representing such Securities, deliver or cause to be delivered to the Purchaser
      a certificate representing such Securities that is free from all restrictive
      and
      other legends.

    


    (d)           The
      Purchaser agrees that stop transfer instructions have been or will be placed
      with respect to the Securities so as to restrict the resale, pledge,
      hypothecation or other transfer thereof and that the Company’s stock transfer
      agent will not be required to accept for registration of transfer any
      Securities, except upon presentation of evidence satisfactory to the Company
      and
      the transfer agent that the restrictions set forth in this Agreement have been
      complied with.  The Purchaser also agrees that stop transfer
      instructions described in the preceding sentence will be placed with respect
      to
      any new certificate representing the Securities upon presentment by the
      Purchaser of a certificate for transfer.


    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    


    5.2           Reservation
      and Listing of Securities.

    


    (a)           The
      Company shall maintain a reserve from its duly authorized shares of Common
      Stock
      for issuance pursuant to the Transaction Documents in such amount as may be
      required to fulfill its obligations in full under the Transaction
      Documents.

    


    (b)           The
      Company shall (i) in the time and manner required by each Trading Market,
      prepare and file with such Trading Market an additional shares listing
      application covering all of the shares of Common Stock issued or issuable under
      the Transaction Documents, (ii) take all steps necessary to cause such
      shares of Common Stock to be approved for listing on each Trading Market as
      soon
      as possible thereafter, (iii) provide to the Purchasers evidence of such
      listing, and (iv) maintain the listing of such Common Stock on each such
      Trading Market.

    


    5.3           Reports
      and Filing.  Upon execution of this Agreement, the Company shall
      fully cooperate with the Purchaser in preparing, drafting and filing the reports
      the Purchaser must file with the relevant government authorities, agencies,
      offices and other institutions in connection with the acquisition of foreign
      securities by the Purchaser. The Purchaser shall fully cooperate with the
      Company in preparing, drafting and filing any reports and documents pursuant
      to
      the relevant securities laws and regulations.

    


    5.4           General
      Indemnity.  The Company agrees to indemnify and hold harmless the
      Purchaser and its directors, officers, affiliates, agents, successors and
      assigns from an against any and all losses, liabilities, deficiencies, costs,
      damages and expenses (including, without limitation, reasonable attorneys’ fees,
      charges and disbursements) incurred by the Purchaser as a result of any
      inaccuracy in or breach of the representations, warranties or covenants made
      by
      the Company herein.  The Purchaser agrees to indemnify and hold
      harmless the Company and its directors, officers, affiliates, agents, successors
      and assigns from and against any and all losses, liabilities, deficiencies,
      costs, damages and expenses (including, without limitation, reasonable
      attorneys’ fees, charges and disbursements) incurred by the Company as a result
      of any inaccuracy in or breach of the representations, warranties or covenants
      made by such the Purchaser herein.

    


    5.5           Compliance
      with Laws.  So long as the Purchaser beneficially owns any
      Securities, the Company will use reasonable efforts to comply with all
      applicable laws, rules, regulations, orders and decrees of all governmental
      authorities, except to the extent non-compliance (in one instance or in the
      aggregate) would not have a Material Adverse Effect.

    


    5.6           Disbursement
      of Funds.  At the Closing, the Purchaser shall transfer cash in an
      amount equal to the Purchase Price to a separate account of the Company in
      the
      manner specified in Section 2.3(b).

    


    5.7           Antidilution.

    


    (a)           If,
      at any time prior to the second anniversary of the Initial Closing Date, the
      Company issues Additional Shares of Stock at an effective net price to the
      Company (the “Diluted Price”) that is less than the Adjusted Purchase
      Price, then within ten Business Days of such issuance, the Company shall issue
      to the Purchaser an additional number of shares of Common Stock equal to the
      Make-Whole Number.  No shares shall be issued pursuant to this
Section 5.7 upon the issuance by the Company of warrants or options
      to purchase Common Stock or preferred stock, and any adjustment in connection
      with such options or warrants shall be made at the time such options or warrants
      are exercised and the Company issues Common Stock or preferred stock, as
      applicable, to the holder thereof (provided that such exercise occurs
      prior to the second anniversary of the Closing Date).  Notwithstanding
      the foregoing or any other provision hereof to the contrary, the Company shall
      not be obligated to issue any Common Stock pursuant to this Section 5.7
      unless the Purchaser purchases all of the Initial Shares as provided
      herein.


    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    


    (b)           For
      purposes of this Section 5.7, the following defined terms shall have
      the following meanings:

    


     “Additional
      Shares of Stock” shall mean all shares of Common Stock and/or preferred
      stock issued by the Company, other than: (1) shares of Common Stock issued
      upon
      conversion of any shares of preferred stock of the Company; (2) shares of Common
      Stock and/or preferred stock and/or warrants and/or options (and the Common
      Stock or preferred stock issued upon the exercise of such warrants and/or
      options) issued before or after the Closing Date to directors, officers,
      employees, consultants and other advisors of the Company and which are approved
      by at least a majority of the Board of Directors of the Company; and (3) shares
      of Common Stock or preferred stock or other rights issued in connection with
      any
      stock dividends, combinations, splits, recapitalizations and the
      like.

    


    “Adjusted
      Initial Shares” means the Initial Shares, as adjusted by the Company for any
      stock dividend, combination, split, recapitalization and the like with respect
      to the Initial Shares occurring after the Closing Date.

    


    “Adjusted
      Purchase Price” means US$1.40 per share of Common Stock,  as
      adjusted by the Company for any stock dividend, combination, split,
      recapitalization and the like with respect to the Initial Shares occurring
      after
      the Closing Date.

    


    “Aggregate
      Consideration” shall mean: (1) to the extent it consists of cash, the net
      amount of cash received by the Company after deduction of any underwriting
      or
      similar commissions, compensation or concessions paid or allowed by the Company
      in connection with such issue or sale; (2) to the extent it consists of property
      other than cash, the fair value of such property as determined by the Board
      of
      Directors of the Company; and (3) if shares of Common Stock or preferred stock
      are issued or sold together with other stock or securities or other assets
      of
      the Company for a consideration that covers both, the portion of the
      consideration so received that may be determined by the Board of Directors
      of
      the Company to be allocable to such shares of Common Stock or preferred
      stock.

    


    “Make-Whole
      Number” means (1)
      the quotient of the Purchase Price divided by the Diluted Purchase Price minus
      (2) the Adjusted Initial Shares.


    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    


    5.8           AMEX
      Listing.  Following the Closing, the Company shall take
      commercially reasonable efforts to cause the Common Stock to be listed for
      trading on the American Stock Exchange within three years from the Closing
      Date.

    


    6.           CONDITIONS.

    


    6.1           Conditions
      Precedent to the Obligations of the Purchaser.  The obligation of
      the Purchaser to acquire Securities at the each Closing is subject to the
      satisfaction or waiver by the Purchaser, at or before the relevant Closing,
      of
      each of the following conditions:

    


    (a)           Representations
      and Warranties.  The representations and warranties of the Company
      contained herein shall be true and correct in all material respects as of the
      date when made and as of the Closing as though made on and as of such date
      (except for those representations and warranties that speak only as of a
      specified date, which shall be true and correct as of such specified
      date);

    


    (b)           Performance.  The
      Company shall have performed, satisfied and complied in all material respects
      with all covenants, agreements and conditions required by the Transaction
      Documents to be performed, satisfied or complied with by it at or prior to
      the
      Closing;

    


    (c)           No
      Injunction.  No statute, rule, regulation, executive order,
      decree, ruling or injunction shall have been enacted, entered, promulgated
      or
      endorsed by any court or governmental authority of competent jurisdiction that
      prohibits the consummation of any of the transactions contemplated by the
      Transaction Documents;

    


    (d)           Material
      Adverse Changes.  Since the date of execution of this Agreement,
      no event or series of events shall have occurred that reasonably would
      reasonably be expected to have or result in a Material Adverse Effect;
      and

    


    (e)           Stockholder
      Approval.  The issuance of the Initial Shares and the Warrants
      shall have been approved by the holders of a majority of the shares of the
      outstanding Common Stock in accordance with all applicable requirements of
      the
      Delaware General Corporation Law and the 1934 Act.

    


    6.2           Conditions
      Precedent to the Obligations of the Company.  The obligation of
      the Company to sell Securities at each Closing is subject to the satisfaction
      or
      waiver by the Company, at or before the relevant Closing, of each of the
      following conditions:

    


    (a)           Representations
      and Warranties.  The representations and warranties of the
      Purchaser contained herein shall be true and correct in all material respects
      as
      of the date when made and as of the Closing as though made on and as of such
      date;

    


    (b)           Performance.  The
      Purchaser shall have performed, satisfied and complied in all material respects
      with all covenants, agreements and conditions required by the Transaction
      Documents to be performed, satisfied or complied with by the Purchaser at or
      prior to the Closing;


    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    


    (c)           No
      Injunction.  No statute, rule, regulation, executive order,
      decree, ruling or injunction shall have been enacted, entered, promulgated
      or
      endorsed by any court or governmental authority of competent jurisdiction that
      prohibits the consummation of any of the transactions contemplated by the
      Transaction Documents;

    


    (d)           No
      Material Adverse Effect.  Since the date of execution of this
      Agreement, no event or series of events shall have occurred that reasonably
      would reasonably be expected to have or result in a Material Adverse Effect;
      and

    


    (e)           Stockholder
      Approval.  The issuance of the Initial Shares and the Warrant
      shall have been approved by the holders of a majority of the shares of the
      outstanding Common Stock in accordance with all applicable requirements of
      the
      Delaware General Corporation Law and the 1934 Act.

    


    7.           MISCELLANEOUS.

    


    7.1           Entire
      Agreement.  The Transaction Documents, together with the Exhibits
      and Schedules thereto, contain the entire understanding of the parties with
      respect to the subject matter hereof and supersede all prior agreements and
      understandings, oral or written, with respect to such matters, which the parties
      acknowledge have been merged into such documents, exhibits and
      schedules.

    


    7.2           Notices.  Any
      and all notices or other communications or deliveries required or permitted
      to
      be provided hereunder shall be in writing and shall be deemed given and
      effective on the earliest of (a) the date of transmission, if such notice
      or communication is delivered via facsimile or e-mail at the facsimile number
      or
      e-mail address specified in this Section 7.2 prior to 18:30 (New York
      City time) on a Trading Day, (b) the Trading Day after the date of
      transmission, if such notice or communication is delivered via facsimile at
      the
      facsimile number specified in this Agreement later than 18:30 (New York City
      time) on any date and earlier than 24:00 (New York City time) on such date,
      (c) the Trading Day following the date of mailing, if sent by nationally
      recognized overnight courier service, or (d) upon actual receipt by the
      party to whom such notice is required to be given.  The address for
      such notices and communications shall be as follows:

    


    
      	
              If
                to the
                Company:                   
                

            	
              Rexahn
                Pharmaceuticals, Inc.

              9620
                Medical Center Drive

              Rockville,
                MD 20850

              Attn:                 Tae
                Heum Jeong

              Fax
                No.:             (240)
                453-5310

              E-Mail:               ted@rexahn.com

            
	 	 
	
              With
                a copy to:

            	
              Chadbourne
                & Parke LLP

              1200
                New Hampshire Avenue, N.W.

              Washington,
                D.C.  20036

              Attn:                
                Hwan Kim

              Fax
                No.:             (202)
                974-6790

              E-Mail:              
                hkim@chadbourne.com

            
	 	 
	
              If
                to the Purchaser:

            	
              Jungwoo
                Family Co., Ltd.

              6F
                Chosuk Bldg, 1550-10

              Seocho-dong,
                Seocho-gu

              Seoul,
                Korea

              Fax
                No.:             82-2-553-4222

              Email:                
                skk1523@hanmail.net

              Attn:                 
                Sung Gwan Kim, CEO

            


    

    


    or
      such
      other address as may be designated in writing hereafter, in the same manner,
      by
      such Person.


    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    


    7.3           Amendments;
      Waivers.  No provision of this Agreement may be waived or amended
      except in a written instrument signed by the Company.  No waiver of
      any default with respect to any provision, condition or requirement of this
      Agreement shall be deemed to be a continuing waiver in the future or a waiver
      of
      any subsequent default or a waiver of any other provision, condition or
      requirement hereof, nor shall any delay or omission of either party to exercise
      any right hereunder in any manner impair the exercise of any such
      right.

    


    7.4           Construction.  The
      headings herein are for convenience only, do not constitute a part of this
      Agreement and shall not be deemed to limit or affect any of the provisions
      hereof.  The language used in this Agreement will be deemed to be the
      language chosen by the parties to express their mutual intent, and no rules
      of
      strict construction will be applied against any party.

    


    7.5           Successors
      and Assigns.  Except as otherwise expressly provided herein, the
      provisions hereof shall be binding upon and inure to the benefit of the parties
      and their successors and permitted assigns.

    


    7.6           No
      Third-Party Beneficiaries.  This Agreement is intended for the
      benefit of the parties hereto and their respective successors and permitted
      assigns and is not for the benefit of, nor may any provision hereof be enforced
      by, any other Person, except that each Indemnitee is an intended third-party
      beneficiary of Section 5.4.

    


    7.7           GOVERNING
      LAW; VENUE; WAIVER OF JURY TRIAL.  ALL QUESTIONS CONCERNING THE
      CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL
      BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE
      REPUBLIC OF KOREA WITHOUT REGARD TO CONFLICTS OF LAWS
      PRINCIPLES.  EACH PARTY HEREBY IRREVOCABLY SUBMITS TO
      THE EXCLUSIVE JURISDICTION OF THE SEOUL CENTRAL DISTRICT COURT OF THE
      REPUBLIC OF KOREA, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
      CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED
      HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION
      DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY
      SUIT,
      ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
      JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS
      IMPROPER.  EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF
      PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR
      PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR
      OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS
      IN
      EFFECT FOR NOTICES TO IT UNDER THIS WARRANT AND AGREES THAT SUCH SERVICE SHALL
      CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING
      CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS
      IN ANY MANNER PERMITTED BY LAW.  THE COMPANY AND THE PURCHASER HEREBY
      WAIVE ALL RIGHTS TO A TRIAL BY JURY.


    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    


    7.8           Survival.  The
      representations, warranties, agreements and covenants contained herein shall
      survive the Closing and the delivery and/or exercise of the Securities for
      a
      period of one year; provided, however, that if the Purchaser sells or
      transfers 50% or more the Initial Shares to any third party, the
      representations, warranties and covenants made by the parties under this
      Agreement immediately shall cease to be effective.

    


    7.9           Execution.  This
      Agreement may be executed in two or more counterparts, all of which when taken
      together shall be considered one and the same agreement and shall become
      effective when counterparts have been signed by each party and delivered to
      the
      other party, it being understood that both parties need not sign the same
      counterpart.  In the event that any signature is delivered by
      facsimile transmission, such signature shall create a valid and binding
      obligation of the party executing (or on whose behalf such signature is
      executed) with the same force and effect as if such facsimile signature page
      were an original thereof.

    


    7.10           Severability.  If
      any provision of this Agreement is held to be invalid or unenforceable in any
      respect, the validity and enforceability of the remaining terms and provisions
      of this Agreement shall not in any way be affected or impaired thereby and
      the
      parties will attempt to agree upon a valid and enforceable provision that is
      a
      reasonable substitute therefor, and upon so agreeing, shall incorporate such
      substitute provision in this Agreement.

    


    7.11           Replacement
      of Securities.  If any certificate or instrument evidencing any
      Securities is mutilated, lost, stolen or destroyed, the Company shall issue
      or
      cause to be issued in exchange and substitution for and upon cancellation
      thereof, or in lieu of and substitution therefor, a new certificate or
      instrument, but only upon receipt of evidence reasonably satisfactory to the
      Company of such loss, theft or destruction and customary and reasonable
      indemnity, if requested.  The applicants for a new certificate or
      instrument under such circumstances shall also pay any reasonable third-party
      costs associated with the issuance of such replacement Securities.

    


    7.12           Remedies.  In
      addition to being entitled to exercise all rights provided herein or granted
      by
      law, including recovery of damages, the Purchaser and the Company will be
      entitled to specific performance under the Transaction Documents.  The
      parties agree that monetary damages may not be adequate compensation for any
      loss incurred by reason of any breach of obligations described in the foregoing
      sentence and hereby agrees to waive in any action for specific performance
      of
      any such obligation the defense that a remedy at law would be
      adequate.


    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    


    7.13           Adjustments
      in Share Numbers and Prices.  In the event of any stock split,
      subdivision, dividend or distribution payable in shares of Common Stock (or
      other securities or rights convertible into, or entitling the holder thereof
      to
      receive directly or indirectly shares of Common Stock), combination or other
      similar recapitalization or event occurring after the date hereof, each
      reference in any Transaction Document to a number of shares or a price per
      share
      shall be amended to appropriately account for such event.

    


    [Signature
      page follows]


    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    


    IN
      WITNESS WHEREOF, the parties have executed this Agreement as of the date first
      above written.

    


    
      	 	
              The
                Company

            
	 	 	 
	 	
              REXAHN
                PHARMACEUTICALS, INC.

            
	 	 
	 	
              By:

            	/s/ Chang
              H. Ahn
	 	
              Name:

            	
              Chang
                H. Ahn

            
	 	
              Title:

            	
              CEO

            
	 	 	 
	 	 	 
	 	
              The
                Purchaser

            
	 	 
	 	
              JUNGWOO
                FAMILY CO., LTD.

            
	 	 
	 	
              By:

            	/s/
              Sung
              Gwan Kim
	 	
              Name:

            	
              Sung
                Gwan Kim

            
	 	
              Title:

            	
              CEO

            


    

    


     [Signature
      page to Securities Purchase Agreement]

    
      
         

         

        20